Universal Diagnostics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Universal Diagnostics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 3 currently recruiting upper quartile by trial count

Universal Diagnostics: 3 sponsored US clinical trials, 3 recruiting.

Universal Diagnostics sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. The most-studied condition in this pipeline is Colorectal Cancer, with 2 trials.

Upper-quartile sponsor footprint

Universal Diagnostics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Universal Diagnostics pipeline

3 recruiting of 3 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Colorectal Cancer (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Universal Diagnostics: open-pipeline peers nationwide

Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Universal Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Universal Diagnostics10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Universal Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Universal Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Universal Diagnostics page

3 registered trials is a research-attention snapshot, not an endorsement of Universal Diagnostics or any single study.

  • 3 of Universal Diagnostics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Colorectal Cancer is the condition Universal Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colorectal Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Universal Diagnostics pipeline card: 3 registered trials from official public datasets.Report a data error.